February 28, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc. Presented positive interim data through 52 weeks and beyond…
February 08, 2025 14:30 ET | Source: 4D Molecular Therapeutics, Inc. 3E10 vg/eye achieved an 83% reduction in injection burden…
January 29, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc. Initial interim 52-week results from Phase 2b Population Extension…